Correction: ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: A multicentre national study (Annals of the Rheumatic Diseases (2017) 76 (1648-1656) DOI: 10.1136/annrheumdis-2016-210802);ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: A multicentre national study

Annals of the Rheumatic Diseases

Volumn 76, Issue 10, 2017, Pages 1648-1656

  Caorsi, Roberta ^a   Penco, Federica ^a   Grossi, Alice ^a   Insalaco, Antonella ^b   Omenetti, Alessia ^a,c   Alessio, Maria ^d   Conti, Giovanni ^e   Marchetti, Federico ^f   Picco, Paolo ^a   Tommasini, Alberto ^g   Martino, Silvana ^h   Malattia, Clara ^a,c   Gallizi, Romina ⁱ   Podda, Rosa Anna ^j   Salis, Annalisa ^c   Falcini, Fernanda ^k   Schena, Francesca ^a   Garbarino, Francesca ^a,c   Morreale, Alessia ^a,c   Pardeo, Manuela ^b   Ventrici, Claudia ^e   Passarelli, Chiara ^b   Zhou, Qing ^l   Severino, Mariasavina ^a   Gandolfo, Carlo ^a   Damonte, Gianluca ^c   Martini, Alberto ^a   Ravelli, Angelo ^a,c   Aksentijevich, Ivona ^l   Ceccherini, Isabella ^a   Gattorno, Marco ^a   more..

^a G GASLINI INSTITUTE   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^e Policlinico di Messina   (Italy)

^f SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^g INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^h REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

ⁱ UNIVERSITY OF MESSINA   (Italy)

^j UNIVERSITY OF CAGLIARI   (Italy)

^k UNIVERSITY OF FLORENCE   (Italy)

^l NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADALIMUMAB; ADENOSINE DEAMINASE; ANAKINRA; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR; CECR1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR;

ADENOSINE DEAMINASE 2 DEFICIENCY; ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CECR1 GENE; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LIVEDO RETICULARIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; ONSET AGE; PATHOPHYSIOLOGY; POLYARTERITIS NODOSA; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SANGER SEQUENCING; SKIN MANIFESTATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DEFICIENCY; DNA MUTATIONAL ANALYSIS; ENZYMOLOGY; GENETICS; HETEROZYGOTE; HOMOZYGOTE; INFANT; ITALY; PEDIGREE; YOUNG ADULT;

ADENOSINE DEAMINASE; ADOLESCENT; AGE OF ONSET; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ITALY; LIVEDO RETICULARIS; MALE; PEDIGREE; POLYARTERITIS NODOSA; STROKE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85026287600     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210802corr1     Document Type: Erratum

References (23)

1. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014;370:911-20.
2. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014;370:921-31.
3. Caorsi R, Penco F, Schena F, et al. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J 2016;14:51.
4. Kaljas Y, Liu C, Skaldin M, et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells. Cell Mol Life Sci 2017;74:555-70.
5. Van Eyck L, Hershfield MS, Pombal D, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol 2015;135:283-7.
6. Van Montfrans JM, Hartman EA, Braun KP, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology 2016;55:902-10.
7. Zavialov AV, Engström A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 2005;391(Pt 1):51-7.
8. Zavialov AV, Yu X, Spillmann D, et al. Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem 2010;285:12367-77.
9. Zavialov AV, Gracia E, Glaichenhaus N, et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 2010;88:279-90.
10. N anthapisal S, Murphy C, Omoyinmi E, et al. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 2016;68:2314-22.
11. Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 2010;69:798-806.
12. Pelagatti MA, Meini A, Caorsi R, et al. Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 2011;63:1141-50.
13. Carta S, Penco F, Lavieri R, et al. Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance. Proc Natl Acad Sci U S A 2015;112:2835-40.
14. Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 2015;125:4196-211.
15. Garg N, Kasapcopur O, Foster J, et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr 2014;173:827-30.
16. Gonzalez Santiago TM, Zavialov A, Saarela J, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol 2015;151:1230-4.
17. Parvathenani LK, Tertyshnikova S, Greco CR, et al. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem 2003;278:13309-17.
18. Westendorp WF, Nederkoorn PJ, Aksentijevich I, et al. Unexplained early-onset lacunar stroke and inflammatory skin lesions: consider ADA2 deficiency. Neurology 2015;84:2092-3.
19. Ettlinger RE, Nelson AM, Burke EC, et al. Polyarteritis nodosa in childhood a clinical pathologic study. Arthritis Rheum 1979;22:820-5.
20. van MJ, Zavialov A, Zhou Q. Mutant ADA2 in vasculopathies. N Engl J Med 2014;371:478.
21. Schepp J, Bulashevska A, Mannhardt-Laakmann W, et al. Deficiency of adenosine deaminase 2 causes antibody deficiency. J Clin Immunol 2016;36:179-86.
22. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
23. Zhu H, Shi X, Ju D, et al. Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice. Inflammation 2014;37:2091-8.